Literature DB >> 4040530

Somatotropic adenoma manifested by galactorrhea without acromegaly.

J Tourniaire, J Trouillas, D Chalendar, A Bonneton-Emptoz, A Goutelle, C Girod.   

Abstract

In two of eight premenopausal women with somatotropic adenomas, galactorrhea was the earliest clinical feature, associated in one patient with amenorrhea. These two patients did not have clinically evident acromegaly. Mean basal serum GH levels were elevated and did not decrease after glucose ingestion. Both patients had modest hyperprolactinemia. Histological and immunocytological studies of the adenomas showed numerous adenomatous somatotropic cells and some alpha-subunit- and PRL-containing cells. In these patients, the origin of the hyperprolactinemia was not clear. In one patient, elevated GH secretion was probably responsible for the galactorrhea, since it disappeared after surgical treatment despite persistence of hyperprolactinemia. In conclusion, galactorrhea, isolated or associated with amenorrhea, can be the only clinical manifestation of a somatotropic adenoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040530     DOI: 10.1210/jcem-61-3-451

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

3.  Aggressive somatotrophinomas lacking clinical symptoms: neurosurgical management.

Authors:  Mario Giordano; Amir Samii; Rudolf Fahlbusch
Journal:  Neurosurg Rev       Date:  2017-12-30       Impact factor: 3.042

4.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

Review 5.  Molecular determinants of pituitary cytodifferentiation.

Authors:  S L Asa; S Ezzat
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

6.  Morphological characterization and subtyping of silent somatotroph adenomas.

Authors:  H Naritaka; T Kameya; Y Sato; S Furuhata; M Otani; T Kawase
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

7.  Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas.

Authors:  Ikuo Kobayashi; Hidehiro Oka; Heiji Naritaka; Yuichi Sato; Kiyotaka Fujii; Toru Kameya
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

8.  Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.

Authors:  M C Vantyghem; C Cortet; C Bauters; M H Gevaert; D Dewailly; J Lefebvre; M Mazzucca
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

Review 9.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

10.  Clinically silent somatotroph adenomas are common.

Authors:  Alisha N Wade; Jennifer Baccon; M Sean Grady; Kevin D Judy; Donald M O'Rourke; Peter J Snyder
Journal:  Eur J Endocrinol       Date:  2011-04-14       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.